



SENT VIA TELEFAX

Dear ANDA Applicant:

The Food and Drug Administration (FDA) has established Docket # 2007N-0382 (<http://www.fda.gov/ohrms/dockets/default.htm>) for comments regarding 180-day generic drug exclusivity for ramipril. Anyone wishing to comment on this subject should submit their comments to the FDA's Dockets Management Branch and reference the docket number cited above. The submission will be on public display in the Dockets Management Branch, Room 1061, Mail Stop HFA-305, 5630 Fishers Lane, Rockville, MD 20852.

If you have any questions, please call Cecelia Parise, Regulatory Policy Advisor to the Director, Office of Generic Drugs, at 240-276-9310.

Sincerely,

Gary J. Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Gary Buehler
10/3/2007 03:05:59 PM